



Office of Technology Transfer and Development
31 Center Drive Room 4A29, MSC2479
Bethesda, MD 20892-2479
Michael Shmilovich, Esq, CLP
shmilovm@mail.nih.gov

August 28, 2019

James Packard Love
Luis Gil Abinader
Dr. Manon Anne Ress

IN RE: Prospective Grant of Exclusive Patent License: Radiotherapeutic against Cancers that overexpress Integrin $\alpha v \beta 3$
84 FR 39001 (to Molecular Targeting Technologies, Inc. (MTTI)).

Dear Messrs. Love, Abinader and Dr. Ress:

Thank you for providing us with your comments regarding the aforementioned Federal Register notice. Prior to posting notices of the proposed grant of an exclusive commercial patent licenses, the NIH determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) are satisfied and that the company applying for the license is qualified both technically and financially to take on the development of a product in the proposed field within the scope of the rights owned and licensed by the United States Government. We consider all comments prior to negotiating the proposed license and have considered your comments.

With regards to this license in particular, the scope of the license proposed is reasonable and necessary for incentivizing the company to undertake a difficult endeavor such as producing a radiotherapeutic of this kind on balance with the Government's interest in promoting the public health and public access to drugs.

We have read through and considered the terms and suggestions proffered in your bolded headings. If your organization requests more documentation, such requests should be filed under the Freedom of Information Act. The webpage for the NIH FOIA Office provides more information on filing requests <http://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office/submitted-foia-requests>.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael A. Shmilovich".

Michael A. Shmilovich, Esq., CLP